文献速递头颈外科咽喉与嗓音

帕尼单抗-IRDye800 在经口激光显微手术中改善喉部肿瘤定位

Panitumumab-IRDye800 Improves Laryngeal Tumor Mapping During Transoral Laser Microsurgery.
PubMed 文献 · Laryngoscope · 2023-10-20

本文报道首例使用帕尼单抗-IRDye800 进行荧光引导手术切除 T2N0M0 经声门喉癌的病例。经口激光显微手术是早期喉癌的主要手术方式,但准确肿瘤定位和切缘评估困难,尤其在分块或消融切除及肿瘤范围较广时。肿瘤靶向荧光引导手术经验性地改善了头颈癌患者的肿瘤和切缘识别。

要点

  • 经口激光显微手术是早期喉癌的主要手术方式,肿瘤学结局与放疗相当。
  • 准确肿瘤定位和切缘评估困难,尤其在分块或消融切除及肿瘤范围较广时。
  • 本文首次报道使用帕尼单抗-IRDye800 荧光引导手术切除 T2N0M0 经声门喉癌。

核心结论

  • 本文首次详细描述了使用帕尼单抗-IRDye800 进行荧光引导手术切除 T2N0M0 经声门喉癌的病例。

研究设计与样本

  • 病例报告,描述一例 T2N0M0 经声门喉癌患者的荧光引导手术切除。

主要发现

  • 帕尼单抗-IRDye800 是一种共价连接近红外染料的表皮生长因子受体单克隆抗体。
  • 肿瘤靶向荧光引导手术在头颈癌患者中经验性地改善了肿瘤和切缘识别。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transoral laser microsurgery represents the primary surgical modality for early laryngeal cancers with oncologic outcomes equivalent to radiotherapy. Accurate tumor mapping and margin assessment can be difficult, however, particularly during piecemeal or ablative resections, and for tumors with a wider geographic footprint. Tumor-targeted fluorescence-guided surgery in patients with head and neck cancer has empirically improved tumor and margin identification; this case details, for the first time, a fluorescence-guided surgical resection of a T2N0M0 transglottic tumor using panitumumab-IRDye800, an epidermal growth factor receptor monoclonal antibody covalently linked to near-infrared (NIR) dye. Laryngoscope, 134:1837-1841, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Bailey L, Stone LD, Gonzalez ML, et al. Panitumumab-IRDye800 Improves Laryngeal Tumor Mapping During Transoral Laser Microsurgery. Laryngoscope. 2023. PMID: 37860983. doi:10.1002/lary.31078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。